-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing's biomedical industry is moving towards the world's cutting-edge highland and high-quality development in the medical and health field.
In this process, the Beijing Daxing Biomedical Industry Base plays an important role
.
Nowadays, the "performance" of Daxing Biopharmaceutical Industrial Base is showing an explosive growth momentum, and its economic indicators have reached a record high
.
According to data, from January to August 2021, the industrial output value of 66 regulated companies in the Daxing Biopharmaceutical Industrial Base increased by 838% year-on-year to 129.
7 billion, accounting for more than 40% of the city's total output value of the biopharmaceutical industry; tax revenue increased by 891% year-on-year.
Reaching 13.
09 billion yuan, the "report card" is particularly eye-catching, achieving the goal of a 100 billion-level industrial park ahead of schedule
.
The data also shows that there are now more than 5,000 companies in the park, including 167 high-tech companies, 18 listed companies, and 66 regulated industrial companies, an increase of two-thirds from the beginning of 2017
.
At the same time, pharmaceutical companies have gradually entered a period of high-yield effectiveness after a period of high investment in construction.
High-growth companies have released their production potential and burst out, driving the rapid improvement of the park's comprehensive strength
.
Daxing Biopharmaceutical Industry Base is promoting the construction of "two districts" with high quality, and strives to create a highland for the cutting-edge transformation of biomedicine in the world
.
Daxing Biopharmaceutical Base is the "Beijing National Bioindustry Base" and "National Demonstration Base for New-type Industrialization Industry".
Now Daxing Biopharmaceutical Industrial Base is forging increasingly powerful production capacity
.
The base currently covers an area of about 13 square kilometers.
According to this calculation, its output value per square kilometer has rushed to the 5 billion mark this year
.
It is understood that the base has gathered the China Institute for Food and Drug Control, the Chinese Academy of Medical Sciences and other pharmaceutical testing and drug research and development institutions, and has attracted Fresenius Kabi, as well as other companies such as Kexing Zhongwei, Minhai Biology, and Hotview Biology.
A batch of domestic and foreign leading pharmaceutical companies with advanced technology has formed a "1+4" with R&D and inspection as the leading sector, biopharmaceuticals, modern Chinese medicine, innovative chemical drugs, and medical devices as the main sectors, and general health and animal medicine as the expansion sectors.
+2" industrial structure, becoming an important bearing area for the country to develop high-end medical and health industries and technological innovation
.
It is estimated that by 2025, the Daxing Biopharmaceutical Industry Base will have a complete industrial, R&D, and service system with a sound structure and a gradual increase in investment in production services.
The development environment of the life and health industry will reach the international advanced level, and it will be built into a domestic life and health technology model.
The source of innovation, build a well-known international exchange center for life and health at home and abroad, and make the integration of "two industries" an important support for promoting the high-quality development of manufacturing
.
Nowadays, the industrial agglomeration effect of the Daxing Biomedical Base has become increasingly prominent, and more and more leading biomedical companies have landed here one after another
.
For example, the total investment of Kexing Zhongwei in the base has exceeded 3 billion yuan
.
Beijing Watson Innovative Biotechnology Co.
, Ltd.
will also invest 2 billion yuan to build a Watson Bio-Industrial Park project in the base to meet the production needs of the 9-price HPV cervical cancer vaccine and other innovative vaccines.
The project is planned to be put into production in 2023, and the annual output value will not be Less than 5 billion yuan
.
The author was also informed that as of the end of August this year, there were 486 newly registered projects in Daxing Biomedical Base, of which 104 were over 10 million
.
New contracted projects include Beilai Biological Stem Cell Project, Hengdao Medical Pathology Diagnosis Center Project, Kayudi Biomolecular Diagnosis Project, etc.
, and 133 new reserve projects, including Huaxi Biohyaluronic Acid Project and Guangdong Opumandi Fluorescence endoscope
.
Now Daxing Biomedical Base is continuously injecting innovation-driven vitality
.
It is reported that it will strive to complete the overall transformation of the park within five years, build a highland for the transformation of Beijing's biomedicine world, and promote the "China Medicine Valley" brand to establish itself in China and go global
.
In this process, the Beijing Daxing Biomedical Industry Base plays an important role
.
Nowadays, the "performance" of Daxing Biopharmaceutical Industrial Base is showing an explosive growth momentum, and its economic indicators have reached a record high
.
According to data, from January to August 2021, the industrial output value of 66 regulated companies in the Daxing Biopharmaceutical Industrial Base increased by 838% year-on-year to 129.
7 billion, accounting for more than 40% of the city's total output value of the biopharmaceutical industry; tax revenue increased by 891% year-on-year.
Reaching 13.
09 billion yuan, the "report card" is particularly eye-catching, achieving the goal of a 100 billion-level industrial park ahead of schedule
.
The data also shows that there are now more than 5,000 companies in the park, including 167 high-tech companies, 18 listed companies, and 66 regulated industrial companies, an increase of two-thirds from the beginning of 2017
.
At the same time, pharmaceutical companies have gradually entered a period of high-yield effectiveness after a period of high investment in construction.
High-growth companies have released their production potential and burst out, driving the rapid improvement of the park's comprehensive strength
.
Daxing Biopharmaceutical Industry Base is promoting the construction of "two districts" with high quality, and strives to create a highland for the cutting-edge transformation of biomedicine in the world
.
Daxing Biopharmaceutical Base is the "Beijing National Bioindustry Base" and "National Demonstration Base for New-type Industrialization Industry".
Now Daxing Biopharmaceutical Industrial Base is forging increasingly powerful production capacity
.
The base currently covers an area of about 13 square kilometers.
According to this calculation, its output value per square kilometer has rushed to the 5 billion mark this year
.
It is understood that the base has gathered the China Institute for Food and Drug Control, the Chinese Academy of Medical Sciences and other pharmaceutical testing and drug research and development institutions, and has attracted Fresenius Kabi, as well as other companies such as Kexing Zhongwei, Minhai Biology, and Hotview Biology.
A batch of domestic and foreign leading pharmaceutical companies with advanced technology has formed a "1+4" with R&D and inspection as the leading sector, biopharmaceuticals, modern Chinese medicine, innovative chemical drugs, and medical devices as the main sectors, and general health and animal medicine as the expansion sectors.
+2" industrial structure, becoming an important bearing area for the country to develop high-end medical and health industries and technological innovation
.
It is estimated that by 2025, the Daxing Biopharmaceutical Industry Base will have a complete industrial, R&D, and service system with a sound structure and a gradual increase in investment in production services.
The development environment of the life and health industry will reach the international advanced level, and it will be built into a domestic life and health technology model.
The source of innovation, build a well-known international exchange center for life and health at home and abroad, and make the integration of "two industries" an important support for promoting the high-quality development of manufacturing
.
Nowadays, the industrial agglomeration effect of the Daxing Biomedical Base has become increasingly prominent, and more and more leading biomedical companies have landed here one after another
.
For example, the total investment of Kexing Zhongwei in the base has exceeded 3 billion yuan
.
Beijing Watson Innovative Biotechnology Co.
, Ltd.
will also invest 2 billion yuan to build a Watson Bio-Industrial Park project in the base to meet the production needs of the 9-price HPV cervical cancer vaccine and other innovative vaccines.
The project is planned to be put into production in 2023, and the annual output value will not be Less than 5 billion yuan
.
The author was also informed that as of the end of August this year, there were 486 newly registered projects in Daxing Biomedical Base, of which 104 were over 10 million
.
New contracted projects include Beilai Biological Stem Cell Project, Hengdao Medical Pathology Diagnosis Center Project, Kayudi Biomolecular Diagnosis Project, etc.
, and 133 new reserve projects, including Huaxi Biohyaluronic Acid Project and Guangdong Opumandi Fluorescence endoscope
.
Now Daxing Biomedical Base is continuously injecting innovation-driven vitality
.
It is reported that it will strive to complete the overall transformation of the park within five years, build a highland for the transformation of Beijing's biomedicine world, and promote the "China Medicine Valley" brand to establish itself in China and go global
.
